Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Complex molecular and metabolic phenotypes depict cancers as a constellation of different
diseases with common themes. Precision imaging of such phenotypes requires flexible and …

Purpose: We recently identified CD46 as a novel therapeutic target in prostate cancer. In this
study, we developed a CD46-targeted PET radiopharmaceutical,[89Zr] DFO-YS5, and …

Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is an integral membrane
protein that is highly up-regulated on the cell surface of several human cancers, making it a …

Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a relatively newly identified
target in prostate cancer. We evaluated the ability of PET/CT with 89Zr-DFO-MSTP2109A, an …

Cancer is a global health issue that impairs the life quality of patients and origins thousands
of deaths annually worldwide. Six-transmembrane epithelial antigen of the prostate …

A six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a newly identified target in
prostate cancer. The use of radio-labeled STEAP1-targeting antibodies with positron …

Materials and methods: We reviewed the literature for prostate cancer PET tracers that are
either being used for patient management or being evaluated in clinical research trials. For …

Purpose: Most patients with prostate cancer treated with androgen receptor (AR) signaling
inhibitors develop therapeutic resistance due to restoration of AR functionality. Thus, there is …

Mesothelin is a tumor differentiation antigen expressed by epithelial tumors, including
pancreatic cancer. Currently, mesothelin is being targeted with an antibody-drug conjugate …